Apollomics

Also Clin1 (worldwide) solid tumors; APL-106 Clin3 AML (partner: GlycoMimetica); APL-502 Clin3 (China, partner: CTTQ) multiple cancers, Clin0 (worldwide) multiple cancers; APL-101 Clin2 multiple cancers; APL-122 Clin1 oncology; APL-102 Clin1 solid tumors; APL-108 Clin0 multiple myeloma; APL-810 Clin0 GI cancers; APL-801 RD oncology

Apollomics is developing a suite of next-generation therapies to treat cancer. Developing clinical assets requires rigorous preclinical studies and mechanistic and scientific rationale whether the asset is to be used as a monotherapy, a combination therapy or both. Apollomics is using this approach to build a pipeline of therapeutics that fall into three categories: [1] anti-cancer enhancers, [2] tumor inhibitors and [3] immuno-oncology drugs. Apollomic’s lead candidate, APL-101, is a selective and potent, orally-available inhibitor of c-Met, which is overexpressed or mutated in several tumor types. Following successful preclinical and Phase 1 clinical trials, Apollomics is now testing APL-101 in patients with non-small cell lung cancer.

Jobs: